The Southeast Cancer Control Consortium, Inc., (SCCC) is a consortium of 15 communities in a five state area with 16 component sites. They are located in an area including eastern Tennessee, 2 border cities of southern Virginia, throughout North and South Carolina, and one location in Georgia. The catchment of these referral communities is estimated at 7.7 million. Demography of the area reflects a low population density,limited socioeconomic and educational development, and a black to white population of approximately twice the national average. The consortium has 125 participating physicians (oncologists, surgeons, and radiation therapists), with one physician designated as the """"""""Community Leader"""""""" to be responsible for locally coordinating participation in clinical trials and cancer control programs. There are trained support personnel in each community and data management is performed and monitored by competent, trained oncology nurses/clinical research associates. Each of he communities have completed the prescribed assurances for OPRR (office for Protection from Research Risks). NCI approved cancer prevention and clinical trials are open for accrual via our three research bases: Cancer and Leukemia Group B, National Surgical Adjuvant Breast and Bowel Project and the Comprehensive Cancer Center of Wake Forest University. The SCCC Operations Office coordinates the consortium's activities by providing a telephone information service line, monitoring IRB approvals, coordinating protocol participation via monthly (and interim) mailings, conducting on-site visits, providing data management training and continuing education programs, preparing grant reports and coordinating audits by our research bases. The SCCC has been very successful, accruing 3,344 registrations in years 01-08, ranking number one in NSABP CCOP accruals and alternately ranks first or second in CALGB's CCOP accruals. Our cancer prevention participation has been exceptional, with 321 BCPT randomizations and 418 PCPT randomizations at the end of year 08. Our cancer control/prevention goals include escalation of a community based program utilizing volunteers (""""""""Community Advocates"""""""") to effect a broad population impact. This unique program is devised to encourage lifestyle modifications and focus on early detection, especially in high-risk populations, as a method to reduce the morbidity and mortality of cancer across ethnic, minority, and socioeconomic groups. By expanding our recruitment to both clinical trials and prevention studies, as well as focusing on early detection and public education, we are confident that our program will significantly impact, in a positive fashion, the quality and quantity of state of the art cancer care and prevention in the community setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA045808-09
Application #
2092025
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1987-07-01
Project End
2000-05-31
Budget Start
1995-09-25
Budget End
1996-05-31
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Southeast Cancer Control Consortium
Department
Type
DUNS #
876940532
City
Winston-Salem
State
NC
Country
United States
Zip Code
27104
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7

Showing the most recent 10 out of 215 publications